Accelerate biotechnology

Article: Nanodisc offers chance better influenza vaccine

The Dutch newspaper, Leidsch Dagblad, published an article on the TTW-grant that the Leiden University has received to collaborate with private partners ZoBio, and Batavia Biosciences to propel SATIRNTM technology, developed by Batavia Biosciences. The project aims to deliver, amongst others, a better influenza vaccine by use of this membrane protein formulation technology. Full article (in Dutch)


Video: Batavia Biosciences, your biopharmaceutical CDMO

Batavia Biosciences is a biopharmaceutical CDMO with an extensive track record in viral vaccine, viral vector, protein and antibody projects. We aim to significantly contribute to ease human suffering from disease by improving the success rate in the translation of candidate medicines from bench to clinic. We offer our technologies and in-depth knowhow to help…


Webinar: Latest Advancements in Production of Therapeutic Antibodies on E. coli

This webinar will give you insights in the possibilities that E. coli fermentation systems can offer for manufacturing of therapeutic antibodies, including antibody fragments. There will be special focus on our new fermentation technology, SCOPETM  technology: a system for a controlled regulation of protein expression yields in E. coli with a case study to showcase the latest technological advancements….


Article: SIDUS® technology enables first clinical study with live attenuated Zika vaccine

Batavia Biosciences has, with its know-how developed under the SIDUS® technology, extensive expertise in house for the production and testing of viral vector based products, like lentiviral vectors, adenoviral vectors, AAV vectors and Measles vectors. This knowledge covers a broad area; from virus DNA construction and modification, to making research batches and clinical batches, including…


Article: Platform technologies improve protein expression

Platform technologies facilitate development and accelerate commercialization of protein therapeutics. Speed to market is essential in the biopharmaceutical industry today. Manufacturers are seeking mechanisms for increasing efficiencies and reducing costs without compromising the safety and efficacy of their drug products. In addition to exploring novel production methods such as continuous processes and disposable production technology, manufacturers also heavily invest in…


Article: Interview with Alfred Luitjens by Biopharm

Batavia Biosciences uses Biopharm’s BioSolve as process development software. The software enables us to predict the effect of suggested process development steps on, for example the Cost of Goods, and to identify cost drivers. Our Director Cell Technology, Alfred Luitjens was interviewed by Biopharm on how he uses the BioSolve software in his work and…


Article: Tackling the challenges in biosimilar development

Yield is still an area that requires significant improvement for many promising recombinant protein and antibody products. Especially in the field of biosimilars, the ability to manufacture products cost-efficiently has a profound competitive advantage. To facilitate high yield production, Batavia Biosciences has developed STEP®, which enables the creation of stable, mammalian CHO cell lines with…


Article: SIDUS® Technology for viral vector manufacturing

Viral vectors are highly valued in many therapeutic fields given the promise of low cost and safe manufacturing coupled with high product efficacy and an excellent safety profile. Engineered with the use of molecular biology tools, viral vectors from well-known natural viruses such as adeno-associated virus (AAV), lentivirus, adenovirus, or modified vaccinia ankara (MVA) have…